S&P 500   5,063.58 (-0.12%)
DOW   38,905.62 (-0.42%)
QQQ   436.67 (+0.03%)
AAPL   180.58 (-0.32%)
MSFT   404.56 (-0.73%)
META   482.55 (+0.17%)
GOOGL   137.31 (-0.19%)
AMZN   173.56 (-0.67%)
TSLA   199.84 (+0.22%)
NVDA   789.51 (-0.18%)
NIO   5.75 (+1.77%)
AMD   177.23 (+0.69%)
BABA   77.75 (+1.62%)
T   16.62 (+0.12%)
F   12.04 (+0.75%)
MU   91.28 (+2.03%)
CGC   3.56 (+2.59%)
GE   153.64 (-0.73%)
DIS   108.29 (+0.57%)
AMC   4.61 (+3.60%)
PFE   26.97 (-0.77%)
PYPL   59.78 (+0.76%)
XOM   104.30 (+0.05%)
S&P 500   5,063.58 (-0.12%)
DOW   38,905.62 (-0.42%)
QQQ   436.67 (+0.03%)
AAPL   180.58 (-0.32%)
MSFT   404.56 (-0.73%)
META   482.55 (+0.17%)
GOOGL   137.31 (-0.19%)
AMZN   173.56 (-0.67%)
TSLA   199.84 (+0.22%)
NVDA   789.51 (-0.18%)
NIO   5.75 (+1.77%)
AMD   177.23 (+0.69%)
BABA   77.75 (+1.62%)
T   16.62 (+0.12%)
F   12.04 (+0.75%)
MU   91.28 (+2.03%)
CGC   3.56 (+2.59%)
GE   153.64 (-0.73%)
DIS   108.29 (+0.57%)
AMC   4.61 (+3.60%)
PFE   26.97 (-0.77%)
PYPL   59.78 (+0.76%)
XOM   104.30 (+0.05%)
S&P 500   5,063.58 (-0.12%)
DOW   38,905.62 (-0.42%)
QQQ   436.67 (+0.03%)
AAPL   180.58 (-0.32%)
MSFT   404.56 (-0.73%)
META   482.55 (+0.17%)
GOOGL   137.31 (-0.19%)
AMZN   173.56 (-0.67%)
TSLA   199.84 (+0.22%)
NVDA   789.51 (-0.18%)
NIO   5.75 (+1.77%)
AMD   177.23 (+0.69%)
BABA   77.75 (+1.62%)
T   16.62 (+0.12%)
F   12.04 (+0.75%)
MU   91.28 (+2.03%)
CGC   3.56 (+2.59%)
GE   153.64 (-0.73%)
DIS   108.29 (+0.57%)
AMC   4.61 (+3.60%)
PFE   26.97 (-0.77%)
PYPL   59.78 (+0.76%)
XOM   104.30 (+0.05%)
S&P 500   5,063.58 (-0.12%)
DOW   38,905.62 (-0.42%)
QQQ   436.67 (+0.03%)
AAPL   180.58 (-0.32%)
MSFT   404.56 (-0.73%)
META   482.55 (+0.17%)
GOOGL   137.31 (-0.19%)
AMZN   173.56 (-0.67%)
TSLA   199.84 (+0.22%)
NVDA   789.51 (-0.18%)
NIO   5.75 (+1.77%)
AMD   177.23 (+0.69%)
BABA   77.75 (+1.62%)
T   16.62 (+0.12%)
F   12.04 (+0.75%)
MU   91.28 (+2.03%)
CGC   3.56 (+2.59%)
GE   153.64 (-0.73%)
DIS   108.29 (+0.57%)
AMC   4.61 (+3.60%)
PFE   26.97 (-0.77%)
PYPL   59.78 (+0.76%)
XOM   104.30 (+0.05%)
NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

$135.57
-0.01 (-0.01%)
(As of 12:39 PM ET)
Today's Range
$134.52
$135.61
50-Day Range
$120.31
$142.96
52-Week Range
$89.04
$143.35
Volume
153,966 shs
Average Volume
774,917 shs
Market Capitalization
$13.49 billion
P/E Ratio
56.02
Dividend Yield
N/A
Price Target
$137.23

Neurocrine Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
1.6% Upside
$137.23 Price Target
Short Interest
Healthy
1.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.65mentions of Neurocrine Biosciences in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$39.03 M Sold Last Quarter
Proj. Earnings Growth
27.98%
From $4.86 to $6.22 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.91 out of 5 stars

Medical Sector

23rd out of 943 stocks

Biological Products, Except Diagnostic Industry

6th out of 147 stocks


NBIX stock logo

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Stock Price History

NBIX Stock News Headlines

NBIX Dec 2024 200.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
NBIX Mar 2024 120.000 call
NBIX Mar 2024 140.000 put
NBIX Mar 2024 110.000 call
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
2/27/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
1,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$137.23
High Stock Price Target
$165.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+1.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
24 Analysts

Profitability

Net Income
$249.70 million
Pretax Margin
17.60%

Debt

Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$2.61 per share
Book Value
$22.72 per share

Miscellaneous

Free Float
94,930,000
Market Cap
$13.49 billion
Optionable
Optionable
Beta
0.25
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives















NBIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 6 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price target for 2024?

24 brokerages have issued 12 month price objectives for Neurocrine Biosciences' shares. Their NBIX share price targets range from $100.00 to $165.00. On average, they expect the company's stock price to reach $137.23 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2024?

Neurocrine Biosciences' stock was trading at $131.76 at the beginning of 2024. Since then, NBIX stock has increased by 2.5% and is now trading at $135.05.
View the best growth stocks for 2024 here
.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 1,880,000 shares, a drop of 18.6% from the January 15th total of 2,310,000 shares. Based on an average daily trading volume, of 777,000 shares, the short-interest ratio is presently 2.4 days.
View Neurocrine Biosciences' Short Interest
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NBIX earnings forecast
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Wednesday, February, 7th. The company reported $1.44 EPS for the quarter, beating analysts' consensus estimates of $1.13 by $0.31. The firm earned $515.20 million during the quarter, compared to analysts' expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a trailing twelve-month return on equity of 12.85%. The firm's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.88 earnings per share.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.76%), Bellevue Group AG (2.44%), Price T Rowe Associates Inc. MD (1.48%), Point72 Asset Management L.P. (1.40%), Dodge & Cox (1.27%) and DSM Capital Partners LLC (1.24%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBIX) was last updated on 2/27/2024 by MarketBeat.com Staff